Top

Surgical Endoscopy

Published in:

01-01-2014

Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease

Authors: Stefano Picozzi, Carlo Marenghi, Cristian Ricci, Giorgio Bozzini, Stefano Casellato, Luca Carmignani

Published in: Surgical Endoscopy | Issue 1/2014

Abstract

Background

Urologists have not reached a consensus regarding the pre-, intra-, and postoperative management of patients taking antiplatelet agents. This study aimed to evaluate the clinical course of patients receiving antithrombotic monotherapy with acetylsalicylic acid (ASA) 100 mg who underwent transurethral resection of bladder cancer.

Methods

This study was designed to compare the surgical outcomes for 108 transurethral resections of bladder cancer performed for patients taking antiplatelet therapy and for 105 procedures performed for patients who had never taken antiplatelet agents before surgery. Antiaggregant therapy was maintained according to criteria evaluated by a urologist, surgeon, anesthesiologist, and cardiologist. Variables were described using the mean as the location index and using standard deviation as a dispersion index if continuous percentages were used elsewhere. Group comparisons were performed using the t test or the chi-square test for categorical data, and Fisher’s exact test was used where appropriate.

Results

The mean operative time for patients taking ASA was 31 min (range 10–65 min), whereas it was 26 min (range 5–60 min) for control subjects. The difference between pre- and postoperative hemoglobin values was −0.6 g/dl in the group receiving antiplatelet therapy and −0.8 g/dl in the control group (p = 0.0720). Transfusional support was required during four procedures performed for patients taking antiplatelet therapy and during two procedures for the control group (p = 0.242). No adverse cardiac events or anesthesia-related complications occurred. Three patients in the treatment group and two patients in the control group required reintervention to ensure hemostasis during the postoperative period. None of the patients in either group underwent rehospitalization for hematuria after leaving the hospital.

Conclusion

The current results suggest that continued use of anti-aggregant monotherapy does not increase the risk of overall bleeding or reintervention for patients undergoing transurethral resection of bladder neoplasms and that suspending aspirin before such a procedure is therefore unnecessary.

Möllmann H, Nef HM, Hamm CW, Elsässer A (2009) How to manage patients with need for antiplatelet therapy in the setting of (un)planned surgery. Clin Res Cardiol 98:8–15PubMedCrossRef

Eberli D, Chassot PG, Sulser T et al (2010) Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. J Urol 183:2128–2136PubMedCrossRef

Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324:71–86CrossRef

SAS Institute Inc., SAS 9.2 (2000–2004) Help and documentation. SAS Institute Inc., Cary

Carmignani L, Picozzi S, Bozzini G et al (2011) Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis. Transfus Apher Sci 45:275–280PubMedCrossRef

Enver MK, Hoh I, Chinegwundoh FI (2006) The management of aspirin in transurethral prostatectomy: current practice in the UK. Ann R Coll Surg Engl 88:280–283PubMedCentralPubMedCrossRef

Taylor K, Filgate R, Guo DY, Macneil F (2011) A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int 108:45–50PubMedCrossRef

Turna B, Stein RJ, Smaldone MC et al (2008) Safety and efficacy of flexible ureterorenoscopy and holmium: YAG lithotripsy for intrarenal stones in anticoagulated cases. J Urol 179:1415–1419PubMedCrossRef

Vasudeva P, Goel A, Sengottayan VK, Sankhwar S, Dalela D (2009) Antiplatelet drugs and the perioperative period: what every urologist needs to know. Indian J Urol 25:296–301PubMedCentralPubMedCrossRef

10.

Mayor S (2006) Drug-eluting stents are safe for licensed indications, FDA panel says. BMJ 333:1235PubMedCrossRef

11.

Silber S, Albertsson P, Avilés FF et al (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804–847PubMedCrossRef

12.

Carmignani L, Picozzi S (2009) Re: noncardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 95:1537PubMedCrossRef

13.

Eisenstein EL, Anstrom KJ, Kong DF et al (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159–168PubMedCrossRef

14.

Straus SE, Majumdar SR, McAlister FA (2002) New evidence for stroke prevention: scientific review. JAMA 288:1388–1395PubMedCrossRef

15.

Llinas RH (2006) Could discontinuation of aspirin therapy be a trigger for stroke? Nat Clin Pract Neurol 2:300–301PubMedCrossRef

16.

Cook LJ, Cottrell AM (2010) Anti-platelet agents in urology. BJU Int. www.bjui.org/FileStreaming.aspx?fileid=311

17.

Di Minno MN, Prisco D, Ruocco AL, Mastronardi P, Massa S, Di Minno G (2009) Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med 4:279–288PubMedCrossRef

18.

Chassot PG, Delabays A, Spahn DR (2007) Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99:316–328PubMedCrossRef

19.

Samama CM, Bastien O, Forestier F et al (2002) Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001—summary statement. Can J Anaesth 49:S26–S35PubMed

20.

Urmey WF, Rowlingson J (1998) Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Reg Anesth Pain Med 23:146–151PubMed

21.

Horlocker TT, Wedel DJ, Benzon H et al (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28:172–197PubMed

22.

Horlocker TT, Wedel DJ, Rowlingson JC et al (2010) Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (third edition). Reg Anesth Pain Med 35:64–101PubMedCrossRef

23.

Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ (1997) Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation 96:1882–1887PubMedCrossRef

24.

Eagle RA, Berger PB, Calkins H et al (2002) ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 94:1052–1064PubMedCrossRef

25.

de Korte FI, van Werkum JW, Vijverberg PL, Ten Berg JM (2008) Late coronary stent thrombosis complicating urologic surgery. Eur Urol 54:221–225PubMedCrossRef

26.

Carmignani L, Picozzi S, Stubinski R et al (2011) Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. Surg Endosc 25:2281–2287PubMedCrossRef

27.

Ehrlich Y, Yossepowitch O, Margel D, Lask D, Livne PM, Baniel J (2007) Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. J Urol 178:524–528PubMedCrossRef

Title: Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease
Authors: Stefano Picozzi
Carlo Marenghi
Cristian Ricci
Giorgio Bozzini
Stefano Casellato
Luca Carmignani
Publication date: 01-01-2014
Publisher: Springer US
Published in: Surgical Endoscopy / Issue 1/2014
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-013-3136-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

The feasibility of delivering a duodenal–jejunal bypass liner (endobarrier) endoscopically with patients under conscious sedation

Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial

National disparities in laparoscopic colorectal procedures for colon cancer

A novel liver retractor for reduced or single-port laparoscopic surgery

Can virtual reality simulators be a certification tool for bariatric surgeons?

Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique